E A M Heijnsdijk
Affiliation: Erasmus MC
Country: The Netherlands
- The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health IndexEveline A M Heijnsdijk
Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands Electronic address
Value Health 19:153-7. 2016..The Beckman Coulter Prostate Health Index (PHI) testing demonstrates improved specificity compared with the PSA-only screening and therefore may improve the cost-effectiveness of prostate cancer detection...
- Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC dataE A M Heijnsdijk
Department of Public Health EAMH, TMdC, EMW, HJdK and Department of Urology CHB, FHS, MJR, Erasmus Medical Center, Rotterdam, the Netherlands Tampere School of Health Sciences, University of Tampere, Tampere, Finland AA Unit of Epidemiology, Institute for Cancer Prevention, Florence, Italy MZ Provinciaal Instituut voor Hygiëne, Antwerp, Belgium VN, LD Department of Urology, Kantonsspital Aarau, Aarau, Switzerland MK, FR Department of Urology, Centre Hospitalier Regional Universitaire, Lille, France AV Department of Urology, Hospital de Fuenlabrada, Madrid, Spain AP Centre for Cancer Prevention, Queen Mary University of London, UK SMM Department of Urology, Tampere University Hospital and University of Tampere, Tampere, Finland TLJT Oncology Center, Antwerp, Belgium LD Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden SVC, Taiwan
J Natl Cancer Inst 107:366. 2015..However, alternative prostate-specific antigen (PSA) screening strategies for the population may exist, optimizing the effects on mortality reduction, quality of life, overdiagnosis, and costs...
- Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigenAndrew J Vickers
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
BMC Med 12:26. 2014..We aimed to estimate the effect on overdiagnosis of restricting prostate specific antigen (PSA) testing by age and baseline PSA...
- Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trialSepideh Saadatmand
Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands
BMC Cancer 12:440. 2012..The aim of the Familial MRI Screening Study (FaMRIsc) is to compare the efficacy of MRI screening to mammography for women with a familial risk. Furthermore, we will assess the influence of breast density...
- Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combinedEveline A M Heijnsdijk
Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
Cancer Epidemiol Biomarkers Prev 21:1458-68. 2012..Clinical observations suggest important differences in the natural history between breast cancers due to mutations in BRCA1 and BRCA2, potentially requiring different screening guidelines...
- Quality-of-life effects of prostate-specific antigen screeningEveline A M Heijnsdijk
Department of Public Health, Erasmus Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
N Engl J Med 367:595-605. 2012..However, the extent to which harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain...
- Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancerE A M Heijnsdijk
Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
Br J Cancer 101:1833-8. 2009..Overdetection and overtreatment are substantial unfavourable side effects with consequent healthcare costs. In this study the effects of introducing widespread PSA screening is evaluated...
- Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factorsE M Wever
Department of Public Health, Erasmus Medical Center, P O Box 2040, Rotterdam, 3000, CA, The Netherlands
Br J Cancer 108:1971-7. 2013..We quantified how the benefits and harms of immediate treatment vary according to the prognostic factors of clinical T-stage, Gleason score, and patient age...
- To be screened or not to be screened? Modeling the consequences of PSA screening for the individualE M Wever
Department of Public Health, Erasmus Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands
Br J Cancer 107:778-84. 2012..We estimated benefits and adverse effects of PSA screening for individuals who are deciding whether or not to be screened...
- Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervalsN T van Ravesteyn
Department of Public Health, Erasmus MC, PO Box 2040, Rotterdam 3000 CA, The Netherlands
Br J Cancer 105:1082-8. 2011..In this study, the trial is simulated in order to gain insight into the results of the trial and to predict the effect of different screening intervals on breast cancer mortality...
- Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deathsR de Gelder
Erasmus MC, Department of Public Health, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
Br J Cancer 104:1214-20. 2011..Because the radiation risk increases with lower exposure age, advancing the lower age limit may affect the balance between screening benefits and risks. The present study explores the benefit-risk ratio of screening before age 50...
- Swiss Medical Board Mammography screening predictions for Switzerland: importance of time-periodsH J de Koning
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
J Med Screen 22:201-6. 2015..We compared these suggested predicted effects with other estimates...